Pipeline

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. We are developing our lead oncology product candidate REQORSA to be administered with targeted therapies and with immunotherapies for NSCLC and SCLC. We continue to conduct preclinical research to explore how REQORSA may be administered with targeted therapies and immunotherapies in other solid tumors, such as ALK-positive NSCLC, NSCLC progressing after rat sarcoma virus (“RAS”) inhibitors, mesotheliomas, and gliomas, and we are researching how other cancer fighting genes, such as NPRL2, can enhance our portfolio using our systemic, non-viral gene therapy platform, the ONCOPREX Delivery System. Using a different gene therapy delivery system, we are also developing our preclinical diabetes candidate GPX-002 for both Type 1 diabetes and Type 2 diabetes. The following table summarizes our product development pipeline. The following table summarizes our product development pipeline as of May 13, 2026 (the filing of our Quarterly Report on Form 10-Q).

Tagrisso® is a registered trademark of AstraZeneca.

Tecentriq® is a registered trademark of Genentech.